62 related articles for article (PubMed ID: 342319)
1. HI antibody response in volunteers vaccinated with live influenza A/New Jersey/76 vaccine.
Ikić D; Smerdel S; Manhalter T; Pasini N; Delimar N
Dev Biol Stand; 1977 Jun 1-3; 39():67-71. PubMed ID: 342319
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of influenza A/New Jersey/76 virus strain, preparation of live vaccine and vaccine reactogenicity in volunteers.
Ikić D; Pasini N; Hećimović M; Juzbasić M; Smerdel S; Rajner N; Jelavić V
Dev Biol Stand; 1977 Jun 1-3; 39():61-5. PubMed ID: 342318
[TBL] [Abstract][Full Text] [Related]
3. A placebo-controlled dose-response study of the reactogenicity and immunogenicity of a cold-adapted recombinant A/Victoria/3/75 (H3N2) live influenza virus candidate vaccine in healthy volunteers.
Hrabar A; Vodopija I; André FE; Mitchell JR; Maassab HF; Hennessy AV; Davenport FM
Dev Biol Stand; 1977 Jun 1-3; 39():53-60. PubMed ID: 342317
[No Abstract] [Full Text] [Related]
4. E-rosette forming cells and humoral antibody titres in humans after vaccination with three different inactivated influenza virus vaccines A/USSR/92/77 (H1N1).
Schmidt S; Süss J; Oehring H; Schmidt J
Acta Virol; 1982 Dec; 26(6):466-73. PubMed ID: 6132540
[TBL] [Abstract][Full Text] [Related]
5. Persistence of influenza A/New Jersey/76 (Hsw1N1) antibody one year after vaccination.
Noble GR; Kaye HS; O'Brien RJ; Kendal AP; Bregman DJ; Wright PF; Amler RW; Dowdle WR
Dev Biol Stand; 1977 Jun 1-3; 39():253-60. PubMed ID: 604107
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of hemagglutination-inhibition (HI) antibodies in gilts of breeding age by large dosages of human A/New Jersey/76 influenza vaccine.
Woods GT; Mansfield ME
Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):399-402. PubMed ID: 461965
[TBL] [Abstract][Full Text] [Related]
7. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
[TBL] [Abstract][Full Text] [Related]
8. Persistence of influenza serum antibodies in humans following immunization with a bivalent A/Victoria and A/New Jersey vaccine.
Boucher DW; Contreras G; Furesz J
Can Med Assoc J; 1979 Apr; 120(7):799-802, 831. PubMed ID: 427686
[TBL] [Abstract][Full Text] [Related]
9. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years.
Nabeshima S; Kashiwagi K; Murata M; Kanamoto Y; Furusyo N; Hayashi J
J Med Virol; 2007 Mar; 79(3):320-5. PubMed ID: 17245715
[TBL] [Abstract][Full Text] [Related]
10. A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination.
White WG; Freestone DS; Bowker CH; Barnes GM; Letley E; Ferris RD
Dev Biol Stand; 1976; 33():202-6. PubMed ID: 782970
[TBL] [Abstract][Full Text] [Related]
11. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials with a new influenza subunit vaccine in adults and children.
Kunz C; Hofmann H; Bachmayer H; Liehl E; Moritz AJ
Dev Biol Stand; 1977 Jun 1-3; 39():297-302. PubMed ID: 342311
[TBL] [Abstract][Full Text] [Related]
13. A trial of live virus intra-nasal influenza vaccine.
Dodge JS
N Z Med J; 1978 Feb; 87(605):79-82. PubMed ID: 273801
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of live recombinant influenza vaccine.
Stealey VM; McCahon D; Freestone DS
Dev Biol Stand; 1976; 33():191-6. PubMed ID: 955267
[TBL] [Abstract][Full Text] [Related]
16. Comparison of one- and two-dose regimens of influenza vaccine for elderly men.
Levine M; Beattie BL; McLean DM
CMAJ; 1987 Oct; 137(8):722-6. PubMed ID: 3651943
[TBL] [Abstract][Full Text] [Related]
17. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
[TBL] [Abstract][Full Text] [Related]
18. Characteristic of humoral response of elderly to inactivated influenza vaccine.
Siennicka J
Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):389-94. PubMed ID: 9017157
[TBL] [Abstract][Full Text] [Related]
19. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
